4. Conclusions
Deregulation of DPP-IV-like activity was observed in synovial fluid and blood plasma of patients with RA and PsA. The cellular source of soluble DPP-IV-like enzymatic activity remains unclear.
Our results suggest significant contribution of intracellular DASH molecules to the total DPP-IV-like enzymatic activity, at least in FMNC from rheumatoid arthritis patients and in BMNC from both rheumatoid arthritis and osteoarthritis.
DASH subcellular distribution was different in FMNC in patients with rheumatoid arthritis compared to degenerative osteoarthritis.
Altered expression pattern and resulting distorted properties of whole DASH enzymatic activity in both systemic—blood—as well as local—joint—environments may impair processing of mediators involved in the inflammatory processes.
Together, DASH molecules, due to their enzymatic activity, may participate on the pathogenesis of RA and PsA and deserve attention as possible future therapeutic targets
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al, 1988, The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31: 315–324.
Aytac U, Dang NH, 2004, CD26/dipeptidyl peptidase IV: a regulator of immune function and a potential molecular target for therapy. Curr Drug Targets Immune Endocr Metabol Disord. 4: 11–18.
Busek P, Malik R, Sedo A, 2004, Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer. Int J Biochem Cell Biol. 36: 408–421.
Cuchacovich M, Gatica H, Pizzo SV, Gonzalez-Gronow M, 2001, Characterization of human serum dipeptidyl peptidase IV (CD26) and analysis of its autoantibodies in patients with rheumatoid arthritis and other autoimmune diseases. Clin Exp Rheumatol. 19: 673–680.
De Meester I, Durinx C, Bal G, Proost P, Struyf S, Goossens F, Augustyns K, Scharpe S, 2000, Natural substrates of dipeptidyl peptidase IV. Adv Exp Med Biol. 477: 67–87.
Engel M, Hoffmann T, Wagner L, Wermann M, Heiser U, Kiefersauer R, Huber R, Bode W, Demuth HU, Brandstetter H, 2003, The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. Proc Natl Acad Sci U S A. 100: 5063–5068.
Gladman DD, Stafford-Brady F, Chi-Hsing Chang, Lewandovski K, Russel ML, 1990, Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol. 17: 809–812.
Gotoh H, Hagihara M, Nagatsu T, Iwata H, Miura T, 1989, Activities of dipeptidyl peptidase II and dipeptidyl peptidase IV in synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Clin Chem. 35: 1016–1018.
Prevoo ML, van’ t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL, 1995, Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 38: 44–48.
Sedo A, Malik R, 2001, Dipeptidyl peptidase IV-like molecules: homologous proteins or homologos activities? Biochim Biophys Acta. 1550: 107–116.
Sedo A, Malik R, Krepela E, 1998, Dipeptidyl peptidase IV in C6 rat glioma cell line differentiation. Biol Chem. 379: 39–44.
Williams YN, Baba H, Hayashi S, Ikai H, Sugita T, Tanaka S, Miyasaka N, Kubota T, 2003, Dipeptidyl peptidase IV on activated T cells as a target molecule for therapy of rheumatoid arthritis. Clin Exp Immunol. 131: 68–74.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Science+Business Media, Inc.
About this paper
Cite this paper
Balaziova, E., Sedova, L., Mares, V., Vlasicova, K., Sevcik, J., Sedo, A. (2006). Dipeptidyl Peptidase-IV Activity and/or Structure Homologs (DASH): Contributing Factors in the Pathogenesis of Rheumatic Diseases?. In: Lendeckel, U., Reinhold, D., Bank, U. (eds) Dipeptidyl Aminopeptidases. Advances in Experimental Medicine and Biology, vol 575. Springer, Boston, MA . https://doi.org/10.1007/0-387-32824-6_18
Download citation
DOI: https://doi.org/10.1007/0-387-32824-6_18
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-29058-4
Online ISBN: 978-0-387-32824-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)